GlassScriptPhysician profile
Suzanne M Partridge
NPI 1629297932
$910.57
in general payments reported to CMS, 2019-2025
20 companies · $331 in 2025
The $331 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $310 · 2020: $30.19 · 2021: $11.92 · 2022: $10.85 · 2023: $68.81 · 2024: $147 · 2025: $331.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $431 · Education: $117.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $430.78 |
| Education | $116.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $310.26 | 2019 | |
| Abbvie INC. | $132.12 | 2024-2025 | |
| Janssen Biotech, INC. | $99.99 | 2025 | Erleada |
| Novartis Pharmaceuticals Corporation | $90.34 | 2024-2025 | |
| E.R. Squibb & Sons, L.L.C. | $46.77 | 2020-2023 | Opdivo |
| Regeneron Healthcare Solutions, INC. | $42.20 | 2024 | Libtayo |
| Aveo Pharmaceuticals, INC. | $40.89 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $36.90 | 2024-2025 | |
| Glaxosmithkline, LLC. | $36.10 | 2025 | Ojjaara |
| Merck Sharp & Dohme LLC | $35.25 | 2022-2023 | Keytruda |
| Pharmacyclics LLC, An Abbvie Company | $14.29 | 2023 | Epkinly |
| Pfizer INC. | $13.54 | 2023 | |
| Gilead Sciences, INC. | $11.92 | 2021 |
7 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Suzanne Partridge listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.